Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma
{{output}}
Standard treatment for recurrent GBM is not yet established. We present a case demonstrating the benefit of intra-arterial (IA) bevacizumab with blood brain barrier disruption (BBBD) for the treatment of recurrent GBM. A 31 year-old man diagnosed with GBM, fol... ...
